#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3405144	A	Drug metabolism in Sprague-Dawley rat liver S9 fraction assessed as compound remaining at 1 uM after 30 mins by HPLC/MS/MS analysis relative to control	Rattus norvegicus	12	ALA3400032	subcellular format	Scientific Literature
2.	ALA3405145	A	Drug metabolism in rat serum assessed as compound remaining at 1 uM after 30 mins by HPLC/MS/MS analysis relative to control	Rattus norvegicus	12	ALA3400032	cell-free format	Scientific Literature
3.	ALA3405146	A	Drug metabolism in human liver S9 fraction assessed as compound remaining at 1 uM after 30 mins by HPLC/MS/MS analysis relative to control	Homo sapiens	12	ALA3400032	subcellular format	Scientific Literature
4.	ALA3405147	A	Drug metabolism in human serum assessed as compound remaining at 1 uM after 30 mins by HPLC/MS/MS analysis relative to control	Homo sapiens	12	ALA3400032	cell-free format	Scientific Literature
5.	ALA3405148	A	Drug metabolism in Sprague-Dawley rat liver S9 fraction assessed as 2-(3-aminopiperidin-1-yl)-3-(2-chlorobenzyl)-5-methyl-4-oxo-4,5-dihydro-3H-imidazo[4,5-c]quinoline-8-carboxylic acid formation at 1 uM after 30 mins by HPLC/MS/MS analysis relative to control	Rattus norvegicus	9	ALA3400032	subcellular format	Scientific Literature
6.	ALA3405151	A	Drug metabolism in rat serum assessed as 2-(3-aminopiperidin-1-yl)-3-(2-chlorobenzyl)-5-methyl-4-oxo-4,5-dihydro-3H-imidazo[4,5-c]quinoline-8-carboxylic acid formation at 1 uM after 30 mins by HPLC/MS/MS analysis relative to control	Rattus norvegicus	9	ALA3400032	cell-free format	Scientific Literature
7.	ALA3405154	A	Drug metabolism in human liver S9 fraction assessed as 2-(3-aminopiperidin-1-yl)-3-(2-chlorobenzyl)-5-methyl-4-oxo-4,5-dihydro-3H-imidazo[4,5-c]quinoline-8-carboxylic acid formation at 1 uM after 30 mins by HPLC/MS/MS analysis relative to control	Homo sapiens	9	ALA3400032	subcellular format	Scientific Literature
8.	ALA3405157	A	Drug metabolism in human serum assessed as 2-(3-aminopiperidin-1-yl)-3-(2-chlorobenzyl)-5-methyl-4-oxo-4,5-dihydro-3H-imidazo[4,5-c]quinoline-8-carboxylic acid formation at 1 uM after 30 mins by HPLC/MS/MS analysis relative to control	Homo sapiens	9	ALA3400032	cell-free format	Scientific Literature
9.	ALA3405160	A	Permeability of the compound at pH 5 by PAMPA		14	ALA3400032	assay format	Scientific Literature
10.	ALA3405161	A	Permeability of the compound at pH 7.4 by PAMPA		14	ALA3400032	assay format	Scientific Literature
11.	ALA3405177	B	Inhibition of human DPP4	Homo sapiens	4	ALA3400032	single protein format	Scientific Literature
12.	ALA3405179	A	Cmax in rat assessed as 2-(3-aminopiperidin-1-yl)-3-(2-chloro-5-fluorobenzyl)-5-methyl-4-oxo-4,5-dihydro-3H-imidazo[4,5-c]quinoline-8-carboxylic acid level at 10 mg/kg, po	Rattus norvegicus	1	ALA3400032	organism-based format	Scientific Literature
13.	ALA3405353	A	Tmax in rat assessed as 2-(3-aminopiperidin-1-yl)-3-(2-chloro-5-fluorobenzyl)-5-methyl-4-oxo-4,5-dihydro-3H-imidazo[4,5-c]quinoline-8-carboxylic acid level at 10 mg/kg, po	Rattus norvegicus	1	ALA3400032	organism-based format	Scientific Literature
14.	ALA3405356	A	AUC in rat assessed as 2-(3-aminopiperidin-1-yl)-3-(2-chloro-5-fluorobenzyl)-5-methyl-4-oxo-4,5-dihydro-3H-imidazo[4,5-c]quinoline-8-carboxylic acid level at 10 mg/kg, po	Rattus norvegicus	1	ALA3400032	organism-based format	Scientific Literature
15.	ALA3405360	A	Oral bioavailability in rat assessed as 2-(3-aminopiperidin-1-yl)-3-(2-chloro-5-fluorobenzyl)-5-methyl-4-oxo-4,5-dihydro-3H-imidazo[4,5-c]quinoline-8-carboxylic acid level at 10 mg/kg	Rattus norvegicus	1	ALA3400032	organism-based format	Scientific Literature
16.	ALA3405363	P	Solubility of the compound at pH 7.4		4	ALA3400032	small-molecule physicochemical format	Scientific Literature
17.	ALA3405364	P	Solubility of the compound at pH 5.5		4	ALA3400032	small-molecule physicochemical format	Scientific Literature
18.	ALA3406651	P	Solubility of the compound at pH 2.5		4	ALA3400032	small-molecule physicochemical format	Scientific Literature